“Toxicity studies with eptinezumab were conducted in rats, cynomolgus monkeys and rabbits. These species are considered pharmacologically relevant based on the affinity and functional activity of eptinezumab against CGRP from these species.”
High affinity and specificity for rat, rabbit, monkey and human α- and β-CGRP; no off-target binding to related peptides
“Eptinezumab has high affinity and specificity for rat, rabbit, monkey, and human α- and β-CGRP without off target binding to amylin, calcitonin, adrenomedulin, or intermedin/ adrenomedulin-2.”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗
Surrogate molecule
No surrogate; the clinical antibody was tested in rat, rabbit and cynomolgus monkey
“Toxicity studies with eptinezumab were conducted in rats, cynomolgus monkeys and rabbits.”